Sanofi-Aventis v. Teva Pharmaceuticals USA, Inc.

Federal Circuit

Sanofi-Aventis v. Teva Pharmaceuticals USA, Inc.

356 F. App'x 388

CourtCourt of Appeals for the Federal Circuit

DecidedJuly 30, 2009

DocketNo. 2007-1521

StatusPublished

This text of 356 F. App'x 388 (Sanofi-Aventis v. Teva Pharmaceuticals USA, Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Federal Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook

Sanofi-Aventis v. Teva Pharmaceuticals USA, Inc., 356 F. App'x 388 (Fed. Cir. 2009).

Pincite

Opinion

ON MOTION

ORDER

MAYER, Circuit Judge.

Sanofí-Aventis et al. (Sanofi) submit correspondence that the court treats as a motion for summary affirmance and issuance of the mandate. Sanofi states that Teva Pharmaceuticals USA, Inc. consents.

[389]*389This appeal was stayed pending the court’s disposition of Sanofi-Aventis v. Apotex, 2007-1438. In Apotex, the court affirmed the district court’s ruling that Sanofi’s patent was not invalid. Sanofi states that Sanofi and Teva agree that, in light of the court’s disposition in Apotex, this appeal should be disposed of by issuance of a mandate affirming the trial court’s decision.

Accordingly,

IT IS ORDERED THAT:

(1) The motion is granted. The judgment of the United States District Court for the Southern District of New York is summarily affirmed and the mandate is issued herewith.

(2) Each side shall bear its own costs.

Free access — add to your briefcase to read the full text and ask questions with AI